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Background: Small non-coding microRNAs (miR) have important regulatory roles 
and are used as biomarkers of disease. We investigated the relationship between 
lipoproteins and circulating miR-30c, evaluated how they are transported in 
circulation and determined whether statins altered the circulating concentration of 
miR-30c. 
Methods: To determine the relationship between lipoproteins and circulating miR- 
30c, serum samples from 79 subjects recruited from a lipid clinic were evaluated. 
Ultracentrifugation and nanoparticle tracking analysis was used to evaluate the 
transportation of miR-30c in the circulation by lipoproteins and extracellular 
vesicles in three healthy volunteers. Using archived samples from previous 
studies, the effects of 40 mg rosuvastatin (n = 22) and 40 mg pravastatin (n = 24) on 
miR-30c expression was also examined. RNA extraction, reverse transcription-
quantitative real-time polymerase chain reaction was carried out using standard 
procedures. 
Results: When stratified according to total cholesterol concentration, there was 
increased miR-30c expression in the highest compared to the lowest tertile (p=0.035). 
There was significant positive correlation between miR-30c and total- (r=0.367; p= 
0.002) and LDL-cholesterol (r=0.391; p=0.001). We found that miR-30c was 
transported in both exosomes and on HDL3. There was a 3.8-fold increased 
expression of circulating miR-30c after pravastatin treatment for 1-y (p=0.005) but no 
significant change with atorvastatin after 8-weeks (p=0.145). 
Conclusions: This study shows for the first-time in humans that circulating miR-30c 
is significantly, positively correlated with total- and LDL-cholesterol implicating 
regulatory functions in lipid homeostasis. We show miR-30c is transported in both 
exosomes and on HDL3 and pravastatin therapy significantly increased circulating 
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miR-30c expression adding to the pleiotropic dimensions of statins.
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1.0 INTRODUCTION 
Small non-coding microRNAs (miR) are currently a subject of intense research; 
however, their exact roles in different diseases and in physiological regulation 
remains incompletely understood. miR are small (~ 22 nucleotides), non-coding RNA 
which regulate gene expression at the post-transcriptional level via inhibition of the 
translation of messenger RNA (mRNA) or by inducing the degradation of specific 
mRNA (1, 2). In the circulation they are resistant to degradation due in part, to being 
transported by carrier molecules including lipoproteins such as HDL, proteins such 
as argonaute-2 and exosomes, which render them highly stable and they can 
therefore be readily detected in blood samples (3). Thus, they are currently being 
studied as potential biomarkers of diseases. Circulating levels of specific miRs have 
been used as biomarkers to diagnose cancers (4); they have been implicated in the 
pathogenesis of obesity (5), diabetes mellitus (6), coronary artery disease (7) and 
used in the diagnosis of myocardial infarction (8). 
 
High plasma cholesterol concentration is a known major risk factor for 
atherosclerosis. Recently, miRs have been linked to cholesterol homeostasis (9). In 
one study, lentiviral mediated hepatic expression of miR-30c was shown to induce 
the degradation of microsomal triglyceride transfer protein (MTP) mRNA, which is 
the apparatus required for the assembly and secretion of apolipoprotein-B containing 
lipoproteins such as LDL (10). This in turn reduced hyperlipidemia and atherosclerosis 
in mice without causing hepatosteatosis (10). More recently, the delivery of a miR-
30c mimic to the liver diminished diet-induced hypercholesterolemia in C57BL/6J 
mice with long term dose escalation studies showing that miR-30c mimic caused 
sustained reductions in plasma cholesterol with no obvious side effects (11). In 
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addition, miR-30c mimic significantly reduced hypercholesterolemia and 
atherosclerosis in Apoe-/- mice (11). These studies show that miR-30c lowers plasma 
cholesterol and mitigates atherosclerosis by reducing MTP expression and 
lipoprotein production without hepatosteatosis. Furthermore, there is emerging 
evidence that increasing hepatic miR-30c levels may be a viable treatment option for 
reducing hypercholesterolemia and atherosclerosis. 
 
Whether specific circulating miRs are dysregulated in lipid disorders in humans such 
as familial hypercholesterolemia (FH) has not been studied before. We therefore 
hypothesized that circulating miR-30c could reflect tissue level expression and 
therefore serve as a biomarker of cardiovascular and metabolic diseases. To study 
this we examined whether circulating miR-30c was correlated with established 
circulating biomarkers of cardiovascular disease including lipoproteins and 
cholesterol. In addition, in an effort to understand how miR-30c is transported in 
circulation as this would affect any observed associations with lipoproteins, we used 
ultracentrifugation to separate the various lipoprotein fractions to determine in which 
subfraction they were carried. We used nanoparticle tracking analysis to evaluate the 
role of extracellular vesicles, specifically exosomes, in trafficking miR-30c. Previous 
studies have shown that circulating miRs are carried on HDL (12) and to a lesser 
extent on LDL (13), on proteins such as argonaute 2 (14) and in exosomes (15). 
However, these studies did not specifically examine miR-30c and there is therefore 
paucity of data with regard to this. Finally, an emerging concept is whether 
treatments and interventions alter circulating miR concentrations. Indeed one study by 
Ortega et al (5) demonstrated that specific circulating miRs changed (some 
increased whereas others decreased) with bariatric surgery-induced or diet-induced 
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weight loss. To date there is limited data regarding the impact of treatment with 
statins on specific circulating miR concentrations in various population groups. We 
therefore sought to delineate the effect, if any, of statin therapy on circulating miR- 
30c. 
 
Thus, the aims of this study were: a) determine the relationship between lipoproteins, 
triglycerides and circulating miR-30c; b) determine how they are transported in 
circulation; and c) investigate whether statin therapy led to alterations in the 
circulating concentrations of miR-30c.
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2.0 MATERIALS AND METHODS 
2.1 Patients 
To determine the relationship between lipoproteins, triglycerides and circulating miR- 
30c, serum samples from 79 fasted subjects attending the lipid clinic at the Glasgow 
Royal Infirmary were studied. As this was a proof-of-principle study, we did not 
analyse outcomes in these patients in any detail and samples were provided to the 
investigators anonymised. We stratified our cohort into tertiles based on total 
cholesterol concentrations with those < 5 mmol/L in the first tertile (‘normal’ group), 
those between 5.0 – 7.5 mmol/L in the second tertile (’indeterminate group’) and 
those with raised cholesterol >7.5 mmol/L in the third tertile (‘hypercholesterolemia’ 
group) (16).  
 
To evaluate the transportation of miR-30c in circulation by lipoproteins, we studied 
serum samples from three healthy volunteers. Samples from two groups of subjects 
were used to assess the impact of statin therapy on circulating miR-30c 
concentration. For the study involving rosuvastatin all the available remnant 
samples (n = 22 from the original 29) were used (17). In this study, subjects with 
raised cholesterol were used in a cross-over trial to evaluate rosuvastatin 40 mg/d. 
After a 5 week dietary run-in subjects were randomized to treatment or placebo for 8 
weeks, followed by a 4 week washout period and then crossed over to the opposite 
arm of the study for a further 8 weeks. The miR concentrations were determined in 
stored (frozen at -80C) samples from baseline and the end of each treatment 
period. The second group was 24 men from the active arm (i.e. on pravastatin 40 
mg/d) of the West of Scotland Coronary Prevention Study (WOSCOPS) (18), from 
whom stored samples were available for the baseline and one-year time-points. Again 
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the samples had been stored at -80oC. For this study, samples were randomly 
selected by the laboratory technician from the available samples stored in our 
institution using the random number generator function of Excel. 
 
The local Research Ethics Committee approved this study and all volunteers in the 
original studies gave informed written consent. All procedures were conducted in 
accordance with the guidelines of The Declaration of Helsinki. 
 
2.2 Lipid measurements 
All analysis was carried out on the ILAB 600 Clinical Chemistry Analyser, using 
Roche reagents (Burgess Hill, UK). Total-cholesterol, HDL-cholesterol and 
triglyceride were measured by enzymatic-colorimetric methods whereas LDL was 
calculated using the Friedewald equation, where LDL-cholesterol = Total cholesterol – 
HDL cholesterol - (Triglycerides/2.2) and is only valid when the triglyceride 
concentration is less than 4.6 mmol/L or Triglycerides/5.0 if cholesterol and 
triglycerides are reported in mg/dL (to convert Triglyceride mg/dL to mmol/L, multiply 
by 88.5). VLDL-cholesterol (mmol/L) was estimated by dividing the triglycerides by 
2.2.  
 
2.3 Separation of lipoprotein subfractions by centrifugation 
To evaluate how miR-30c is transported in the circulation, serum samples were 
collected into clot activator tubes with gel separator from three healthy volunteers. The 
samples were centrifuged at 10,000 g for 10 minutes at a temperature of 4°C. The 
resultant supernatant was then separated into lipid subfractions by sequential 
centrifugation using density gradient solutions on the Beckman TLA 100.2 
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ultracentrifuge (Beckman Coulter, UK). Briefly, VLDL was first separated by 
overlaying 500 μL of sample with 500 μL of 1.006 g/mL density solution and 
centrifuged at 100,000 g for 2.5 hours at 25°C. To isolate IDL, 500 μL of the 
remaining infranatant from the previous step was mixed with 40 μL of 1.182 g/mL 
density solution and overlaid with 460 μL of 1.019 g/mL density solution and 
centrifuged at 100,000 g for 2.5 hours at 25°C. To isolate LDL, 500 μL of the 
remaining infranatant was mixed with 184 μL of 1.182 g/mL density solution and then 
overlaid with 316 μL of 1.063 g/mL of density solution. This was centrifuged as 
above. To isolate HDL2, 500 μL infranatant was mixed with 88 μL of 1.478 g/mL of 
density solution and then overlaid with 412 μL of 1.125 g/mL density solution, 
centrifuged at 53,000 g for 18 hours at 23°C. Finally to isolate HDL3, 500 μL 
infranatant was mixed with 160 μL of 1.478 g/mL density solution and then overlaid 
with 340 μL of 1.21 g/mL of density solution. This was then centrifuged at 100,000 g 
for 5 hours at 23°C. The remaining infranatant was deemed to be lipid depleted 
(LPDS), which was confirmed by the demonstration of negligible concentrations of 
lipids and apolipoproteins in them (Supplemental Table 1). At each of the above 
steps, 500 uL supernatant was stored at -80°C for the subsequent extraction of RNA. 
 
2.4 Nanoparticle tracking analysis to determine presence of extracellular 
vesicles 
Given that a large percentage of the miRs studied were detected in the lipid-depleted 
subfraction (LPDS), we inferred that they contained extracellular vesicles. To confirm 
this we used nanoparticle tracking analysis (NTA) performed with a NanoSight LM10 
instrument (NanoSight Ltd, Amesbury, UK). NTA captures real-time videos, showing 
particles moving by Brownian motion (19). A 635 nm laser is used to illuminate 
nanoparticles in liquid suspension. The light scattered from the particles can be 
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visualized using a ×20 objective lens of a light microscope that is attached to a camera 
running at 30 frames per second. The speed of moving particles is determined on a 
particle-by-particle basis, and the size is calculated using the Stokes-Einstein 
equation (19). A video of 60 seconds duration was recorded and data analysis was 
carried out using the NTA analytical software version 2.3 (NanoSight Ltd, UK). We 
selected particles of size between 30 and 120 nm, which are known to be specific for 
exosomes (15). 
 
2.5 RNA extraction 
Total RNA including miRs was isolated using the commercial miRNeasyTM kit 
(QIAGEN, Germany) using 200 μL serum from each patient. All samples were spiked 
with 50 pmol/L of synthesized Caenorhabditis elegans miR – cel-miR-39-3p (Applied 
Biosystems/Thermo-Fisher Scientific, UK) – that lacked sequence homology to 
human miRs. This was used to serve as an internal control to monitor extraction 
efficiency and used for data normalisation. According to the manufacturer (QIAGEN, 
Germany), DNAse treatment is not recommended for serum or plasma samples as the 
combined QIAzolTM and RNeasyTM technologies efficiently removes the trace 
amount of DNA. The extracted RNA was eluted into RNAse free water provided in the 
kit and all samples were adjusted to a fixed total RNA concentration of 2 ng/µL prior to 
further use. The final RNA yield and purity was determined by the A260/A280 ratio 
measured by a NanoDrop ND-1000 spectrophotometer (NanoDrop 
Technologies/Thermo-Fisher Scientific, UK) with a ratio 1.70 to 2.00 indicative of 
good RNA purity. The isolated RNA was stored at -80ºC for further use. 
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2.6 Reverse transcription (RT) 
The extracted RNA was reverse transcribed using a commercially available kit 
(Applied Biosystems/Thermo-Fisher Scientific, UK) using miR-specific stem-loop 
primers as per manufacturer instructions. 5 μL of the sample was added to a 96-well 
plate together with 10 μL reaction mixture (MasterMixTM) containing 1.50 μL 10X 
reverse transcription buffer, 0.15 μL dNTP (100 mM), 1.00 μL MultiscribeTM reverse 
transcriptase (50 U/μL), 0.19 μL RNAase inhibitor (20 U/μL), 4.16 μL nuclease-free 
water and 3 μL 5X specific RT primers. The RT was carried out in a PTC-225 Peltier 
Thermal Cycler (MJ Research Inc., Waltham, Massachusetts) at 16°C for 30 min, 
then 42°C for 30 mins, followed by 85°C for 5 mins and then kept at 4°C. A no 
template control (NTC) was included in each experiment to account for 
contamination by genomic DNA. The negative control produced no detectable signal 
in any of the experiments. In all cases, the RT product was quantified immediately by 
qPCR and the remainder stored at -80ºC. 
 
2.7 Gene expression by quantitative real time PCR (qPCR) 
The miRs were quantified using TaqManTM MicroRNA assays (Applied 
Biosystems/Thermo-Fisher Scientific, UK) in a 384 well plate in duplicate. We used 0.7 
μL of the RT product, 5.0 μL TaqManTM Universal PCR MasterMix II – no UNG, 
(Applied Biosystems/Thermo-Fisher Scientific, UK), 3.8 μL RNAse free water and 5 μL 
20X TaqManTM MicroRNA assay. The qPCR was performed using the 7900HT Fast 
Real-Time PCR System (Applied Biosystems, UK) and manually set-up as follows: 
95°C for 10 mins followed by 40 cycles of 95°C for 15 s and 60 °C for 60 s. The 
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quantification cycle (Cq) was determined with instrument default threshold settings 
(10 SDs above the mean fluorescence of the baseline cycle).  
 
All experimental work was carried out in accordance with the Minimum Information 
about Quantitative Real-Time Polymerase Chain Reaction Experiments (MIQE) (20). 
All primer sequences used in this study are given in Supplemental Table 2. The 
precision of the experiments in this study were determined using a nested analysis of 
variation (ANOVA) model (21) and the data is shown in Supplemental Table 3.  
 
2.8 Statistical analysis and data normalization 
The use of a fixed concentration of total RNA in all experiments allowed for direct 
comparisons of the miR expression data across the groups. Quantification cycle (Cq) 
and miR copy number are reciprocal and related by a log2 factor implying a change 
in Cq of 1 represents a 2-fold change in miR copy number. In addition, the lower the 
Cq, the higher the miR expression. Data were normalised by determining ∆Cq, which 
is the difference between the expression of the control miR-39 and miR-30c. Relative 
expression was determined in relation to changes over control (∆∆Cq). The data 
were normally distributed according to the Kolmogorov-Smirnov test and as such 
associations were determined using Pearson correlation. For the comparison of 
more than two normally distributed variables, one-way ANOVA followed by Tukey 
pairwise comparison was undertaken. For the comparison of paired data, paired t- 
test was used. Statistical analyses were undertaken using Minitab version 17.1.0. 
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3.0 RESULTS 
3.1 Association of circulating miR-30c with serum lipids. 
Table 1 shows the laboratory characteristics of the study sample stratified into tertiles 
according to total cholesterol concentration as described in the methods. Of the 79 
subjects studied there were insufficient sample or spoilt analyses in 9 cases. Of the 
remaining 70 subjects, when stratified according to total cholesterol concentration, 
there was significantly increased miR-30c expression in the group with highest 
compared to the lowest tertile (Figure 1A, F = 3.27; p=0.044; the p-values by Tukey 
multiple comparison are shown on the graph). When stratified according to LDL-
cholesterol there was also significantly increased miR-30c expression in the group 
with the highest compared to the lowest tertile (Figure 1B, F = 3.62; p=0.032; the p-
values by Tukey multiple comparison are shown on the graph). In addition, Figure 2 
shows there was significant positive correlation between miR-30c and total 
cholesterol (r=0.367; p= 0.002) and LDL-cholesterol (r=0.391; p=0.001). 
 
3.2 Circulating  miR-30c transportation 
To account for the mode of transportation in circulation, we studied the roles of 
lipoproteins and extracellular vesicles. Figure 3A shows the relative expression of 
miR-30c in each of the lipoprotein and lipid depleted (LPDS) sub-fractions. LPDS 
and HDL3 showed significantly higher relative miR-30c expression (ΔCq = 14.0 ± 0.7 
and 13.8 ± 0.2, respectively) compared to HDL2 (ΔCq = 17.1 ± 0.3), LDL (ΔCq = 19.6 
± 0.6), IDL (ΔCq = 18.3 ± 0.3) and VLDL (ΔCq = 18.8 ± 0.3) (F = 32.54; p<0.0001) 
and were not significantly different from each other. We confirmed the presence of 
exosomes in LPDS as shown in Figure 3B. The mean (SD) particle size was 47 (32) 
nm and the mode was 32 nm, which was the expected size range for exosomes (30- 
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120 nm as shown by vertical demarcations). The mean concentration in a 
representative experiment was 23.3 x 108 exosomes/mL. These data reveal that miR-
30c is present in circulation mainly in exosomes and bound to HDL3 with negligible 
amounts trafficked on other lipoproteins. 
 
3.3 Circulating miR-30c and effect of statin therapy 
Treatment with pravastatin significantly increased mean circulating miR-30c 
expression as shown in Figure 4A (∆Cqbefore =10.8 ± 0.3; ∆Cqafter = 9.8 ± 0.2; 
p=0.005), representing an overall 3.8-fold increase in expression across the subjects 
studied. Of the 24 subjects, 19 showed an increased expression in circulating miR- 
30c as denoted by a decrease in ∆Cq (Figure 4B). Rosuvastatin treatment also 
increased circulating miR-30c expression (15 of 22 subjects) as shown in Figure 4A 
and 4C (∆Cqbefore =17.5 ± 0.3; ∆Cqafter = 16.9 ± 0.3) but the change in expression 
was not found to be statistically significant (p=0.145). 
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4.0 DISCUSSION 
This study shows for the first time a positive correlation between miR-30c and total- 
and LDL-cholesterol in humans. We found that miR-30c is transported in both 
exosomes and by HDL3. In addition, we showed that pravastatin therapy significantly 
increased miR-30c. 
 
4.1 Circulating miR-30c and regulation of cholesterol homeostasis 
We observed a significant, positive correlation between miR-30c and total- and LDL- 
cholesterol. In addition, we found that those with a total cholesterol > 7.5 mmol/L had a 
significantly higher miR-30c than those with <5.0 mmol/L. To the best of our 
knowledge, this is the first such report in humans. A previous study in mice (10) 
showed that miR-30c induced the degradation of MTP mRNA leading to decreased 
secretion of apolipoprotein B. In addition, independently of MTP, miR-30c reduced 
hepatic lipid synthesis eventually attenuating hyperlipidemia and consequently 
mitigating atherosclerosis in animal models (10). A tentative interpretation of our 
finding of increased expression of miR-30c as cholesterol rises is that it is a 
compensatory mechanism activated to decrease the secretion of both lipids and 
lipoproteins when circulating levels are high. It has been suggested that raising miR- 
30c levels might be useful in the treatment of hyperlipidemia and associated 
atherosclerosis (10, 11). The idea that miR-30c may be used as a biomarker for lipid 
disorders such as FH is also an interesting prospect. Given that we showed a clear 
demarcation between those with normal total cholesterol concentrations compared to 
concentrations expected in patients with lipid disorders such as FH, further work in 
large, unselected populations is required to confirm this observation. 
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4.2 Circulating miR-30c transportation 
It is known that miR circulate bound to HDL (12) and to a lesser extent to LDL 
particles (13). However, to the best of our knowledge there is no specific information 
on the lipoprotein-mediated transport of miR-30c. The idea that exosomes offer an 
important mode of intracellular communication is an area of growing interest (22). 
Indeed one landmark study has shown exosomes deliver specific miR via the 
circulation and protect the myocardium from ischemia-reperfusion injury (23) 
whereas another has shown that miRs in exosomes can be therapeutically 
manipulated in circulation to reduce in-stent restenosis (24). Our finding that miR- 
30c is shuttled both in exosomes and by HDL3 opens up the possibility that it may be 
used therapeutically, either by strategies that increase HDL concentrations or by 
manipulating the exosomes that shuttle them. This study also reveals for the first 
time yet another role for the small dense HDL molecule - HDL3 in the transportation of 
miR-30c. It is noteworthy that low HDL3 has been shown to be independently 
associated with a greater risk of myocardial infarction (25). The finding of this study 
that miR-30c is shuttled by HDL3 but yet attenuates total and LDL-cholesterol 
remains to be reconciled. Whether other miRs are carried by HDL3 and the 
implications of that remains to be established. Whether these miRs are responsible for 
the functions of the HDL particles they are carried on remains to be explored. We did 
not account for protein-bound concentrations of circulating miR-30c (14) but this 
is a constant and would not affect the results of this study. 
 
4.3 Circulating miR-30c and effect of statin therapy 
It is well known that statins exert benefits beyond lipid-lowering effects including 
blood-pressure lowering and cardiac remodelling (26). Furthermore, it is becoming 
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clear that lipophilic statins such as atorvastatin might be more potent than hydrophilic 
statins such as pravastatin and rosuvastatin (27). In this study, we showed that 
pravastatin but not rosuvastatin significantly increased circulating miR-30c 
concentration. This might suggest a differential therapeutic effect as both drugs are 
hydrophilic. However, it should be noted that the period of treatment varies 
considerably - 1 year with pravastatin compared to 8 weeks with rosuvastatin, and it 
may take time for the statins to exert an effect on miR-30c expression. The 
pleiotropic effects of statins are a theme of current research (28), and our finding that 
statins augment circulating miR-30c adds to the list of their potential beneficial 
effects. One study (29) examined Chinese patients with unstable angina and sought to 
determine how statin therapy affected their circulating miRs. They found that statins 
induced a significant up-regulation of a number of circulating miR including miR-30c, 
which was increased by 2.1-fold, an observation that is in concordance with the 
findings of this study in a primarily Caucasian population. The mechanism(s) of how 
statins alter circulating miR and the interplay between liver production and 
circulating miR remains to be established. We speculate that this paradoxical effect of 
pravastatin that decreases LDL-cholesterol but yet increases the expression of miR-
30c might be an attempt to independently augment the decreased synthesis of 
lipoproteins in the face of hyperlipidemia but further experimental work is required to 
confirm this hypothesis. 
 
4.4 Strengths and Limitations of this Study 
The strengths of the study are the use of a non-human internal control. The 
normalisation of data derived from studies involving miR is a subject of current 
debate (30). Commonly, studies investigating miR use a housekeeper miR known to 
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be present in the sample, but there is now evidence that these can change due to 
disease (31). The use of an internal standard not expressed in humans such as cel- 
miR-39-3p alleviates this problem (32). In addition, we used a fixed total RNA 
concentration in all experiments allowing for comparisons across groups. The main 
limitation of this study was the sample size and use of archived samples. Archived 
samples provide an invaluable opportunity to test hypotheses. Further work with a 
larger sample size and diverse population groups is required to explore the effects of 
statins but the results reported here are revelatory. 
 
4.5 Conclusions 
This study has shown for the first time that in humans circulating miR- 30c is 
significantly correlated with total- and LDL-cholesterol implicating possible 
regulatory functions in lipid homeostasis. We show that miR-30c is carried in both 
exosomes and on HDL3 and pravastatin therapy significantly increased circulating 
miR-30c expression adding to the pleiotropic dimensions of statins and alluding to 
the possibility of therapeutic manipulation. 
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Table 1. Laboratory characteristics of participants stratified according to total cholesterol concentration. Mean ± standard deviation 
shown. Of 79 subjects studied, there was incomplete data in 9 cases giving a total of 70 across the tertiles. 
 
 All subjects  
(n = 70) 
Tertile 1 
 (n = 16) 
Tertile 2 
(n = 37) 
Tertile 3 
(n = 17) 
p value† 
Total-cholesterol (mmol/L)a 6.36 ± 1.5 4.33 ± 0.4*‡ 6.26 ± 0.7*¶ 8.33 ± 0.6‡¶ <0.0001 
LDL-cholesterol (mmol/L)a 3.96 ± 1.2 2.43 ± 0.3*‡ 3.87 ± 0.8*¶ 5.51 ± 0.5‡¶ <0.0001 
HDL-cholesterol (mmol/L)a 1.43 ± 0.4 1.00 ± 0.2*‡ 1.51 ± 0.4*¶ 1.62 ± 0.4‡¶ <0.0001 
VLDL-cholesterol (mmol/L)a 0.97 ± 0.3 0.96 ± 0.2‡ 0.91 ± 0.2¶ 1.20 ± 0.3‡¶ 0.001 
Triglycerides (mmol/L)b 1.31 ± 0.4 1.31 ± 0.4 1.23 ± 0.3 1.42 ± 0.4 0.201 
aTo convert total-, LDL-, HDL- and VLDL-cholesterol from mmol/L to mg/dL multiply by 38.67; bto convert triglyceride from mmol/L to 
mg/dL multiply by 88.57. †ANOVA to test differences in the means between the tertiles followed by Tukey multiple comparison with 
significant statistical difference shown by * Tertile 1 vs 2; ‡ tertile 1 vs 3; ¶ Tertile 2 vs 3. 
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Figure 1. miR-30c expression stratified as tertiles according to total-cholesterol (A) and LDL-cholesterol 
(B) concentrations. Total cholesterol: tertile 1<5.0 mmol/L (‘normal group’; n = 16); tertile 2 = 5.0-7.5 
mmol/L (‘indeterminate group’; n = 37); tertile 3 > 7.5 mmol/L (‘hypercholesterolemia group’; n = 17). RQ 
– relative quantification following log2 transformation of data. Mean (SE) shown. The p-values by Tukey 
multiple comparisons are shown on the graph. 
Figure 2. Correlation of miR-30c with lipoproteins and triglyceride. Chol – cholesterol, LDL – low density 
lipoprotein, HDL – high density lipoprotein, VLDL – very low density lipoprotein, Trig – triglycerides all 
given on the y axis. The inverse delta Cq is shown on the x axis. The inverse is shown for clarity because 
the higher the Cq the lower the miR expression. All measured in mmol/L. 
Figure 3. A) Expression of miR-30c in various lipoprotein sub-fractions relative to respective 
unseparated serum. RQ – relative quantification following log2 transformation of data. LPDS – lipid-
depleted sub-fraction, HDL – high density lipoprotein-cholesterol, LDL – low density lipoprotein-
cholesterol, IDL – intermediate density lipoprotein-cholesterol, VLDL – very low density lipoprotein-
cholesterol. * LPDS and HDL3 showed significantly higher relative expression compared to the other 
lipoproteins. Mean (SE) shown. B) The presence of exosomes (30-120 nm) in the LPDS. Particle size is 
shown against relative intensity (arbitrary units, AU). Inset – representative video frame of exosomes. 
Figure 4. Effect of 40 mg Pravastatin (n = 24; Figures A & B) and 40 mg Rosuvastatin (n = 22; Figures A 
& C) on circulating miR-30c expression. Figure A shows mean (SE) fold-change whereas B & C show 
individual ΔCq before and after treatment 
  
 
  
 
  
 
  
 
  
Highlights 
This study highlights the following for the first time: 
• miR-30c is positively correlated with total- and LDL-cholesterol implicating specific regulatory 
functions in lipid homeostasis. 
• We show that specific micro-RNAs are transported differently in the circulation with miR-30c 
being transported in both exosomes and on HDL3. 
• This study shows that pravastatin significantly increased circulating miR-30c expression adding 
to the pleiotropic dimensions of statins and demonstrating that circulating miR is amenable to 
therapeutic manipulation. 
